# ClinicalTrials.gov record NCT05313529

> PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05313529-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-06
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05313529-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05313529-liraglutide-v1.json
- Content SHA-256: `89e61b688070c31a6cecd2c1f81392de65a113a5143da9727895434cefa5d885`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05313529 ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`](#source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621))

## Sources

<a id="source-ctg-observation-nct05313529-2026-08-06-c58d3b45f621"></a>
- **ClinicalTrials.gov record NCT05313529 · retained source version 2026-08-06:c58d3b45f621f60f25ac9f31cb95bf9db424252032dd2b6f30977f0590a43db4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05313529) (`ctg-observation-nct05313529-2026-08-06-c58d3b45f621`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05313529." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05313529-liraglutide-v1.json SHA-256: 89e61b688070c31a6cecd2c1f81392de65a113a5143da9727895434cefa5d885.